Retransmitting: Senzime’s Interim report January – March 2017

Financial information first quarter 2017

  • Net sales amounts to KSEK 0 (22)
  • Income after financial items amounts to KSEK -3,970 (-1,850).
  • Earnings per share before dilution amounts to SEK -0.11 kr (-0.12).
  • Cash and cash equivalents per March 31, 2017 equal SEK 3.8 million (11.9).
  • Number of shares per March 31, 2017 amounts to 36,172,643 (16,076,730).

For further information, please contact:

Jessica Roxhed, CFO

Tel: +46 703-94 94 98, e-mail: jessica.roxhed@senzime.com 

TO THE EDITORS  

About Senzime  

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com 

This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on May 23th 2017.